Table 1. Patient’s demographic and clinical characteristics.
| Characteristics | Overall (n=121) | No eosinophilia (n=88) | Eosinophilia (n=33) | P value |
|---|---|---|---|---|
| Gender, n (%) | ||||
| Female | 19 (15.7) | 15 (17.0) | 4 (12.1) | 0.587 |
| Male | 102 (84.3) | 73 (83.0) | 29 (87.9) | |
| Age, years, mean ± SD | 63±10 | 63±9 | 65±10 | 0.345 |
| Smoking status, n (%) | ||||
| Never smoker | 14 (11.6) | 10 (11.4) | 4 (12.1) | 0.726 |
| Current smoker | 51 (42.1) | 39 (44.3) | 12 (36.4) | |
| Former smoker | 56 (46.3) | 39 (44.3) | 17 (51.5) | |
| Comorbidities, n (%) | ||||
| COPD | 38 (31.4) | 25 (28.4) | 13 (39.4) | 0.246 |
| Asthma | 4 (3.3) | 3 (3.4) | 1 (3.0) | 0.917 |
| Allergic rhinitis | 2 (1.7) | 2 (2.3) | 0 | 0.383 |
| Skin disease | 1 (0.8) | 1 (1.1) | 0 | 0.539 |
| Rheumatologic disease | 4 (3.3) | 1 (1.1) | 3 (9.1) | 0.029 |
| ECOG performance status, n (%) | ||||
| 0 | 14 (11.6) | 9 (10.2) | 0.218 | |
| 1 | 89 (73.6) | 63 (71.6) | ||
| 2 | 18 (14.9) | 16 (18.2) | ||
| Histological subtype, n (%) | – | |||
| Adenocarcinoma | 77 (63.6) | 53 (60.2) | 24 (72.7) | |
| Squamous cell carcinoma | 38 (31.4) | 30 (34.1) | 8 (24.2) | |
| Others | 6 (5.0) | 5 (5.7) | 1 (3.0) | |
| Staging at diagnosis, n (%) | ||||
| I–IIIA | 48 (39.7) | 37 (42.0) | 11 (33.3) | 0.383 |
| IIIB–IVB | 73 (60.3) | 51 (58.0) | 22 (66.7) | |
| PD-L1 expression, n (%) | ||||
| <1% | 40 (33.1) | 30 (34.1) | 10 (30.3) | 0.571 |
| 1–49% | 20 (16.5) | 16 (18.2) | 4 (12.1) | |
| 50–100% | 54 (44.6) | 37 (42.0) | 17 (51.5) | |
| Not available | 7 (5.8) | 5 (5.7) | 2 (6.1) | |
| Mutational status, NGS, n (%) | ||||
| Wild-type | 42 (34.7) | 27 (30.7) | 15 (45.5) | – |
| KRAS | 26 (21.4) | 20 (22.7) | 6 (18.2) | |
| EGFR | 5 (4.1) | 4 (4.5) | 1 (3.0) | |
| BRAF | 5 (4.1) | 3 (3.4) | 2 (6.1) | |
| ALK | 3 (2.5) | 3 (3.4) | 0 (0) | |
| Others | 5 (4.1) | 3 (3.4) | 2 (6.1) | |
| Not available | 35 (28.9) | 28 (31.8) | 7 (21.2) | |
| IO drug, n (%) | ||||
| Atezolizumab | 10 (8.3) | 10 (11.4) | 0 | 0.05 |
| Pembrolizumab | 53 (43.8) | 34 (38.6) | 19 (57.6) | |
| Nivolumab | 58 (47.9) | 44 (50.0) | 14 (42.4) | |
| Line of treatment, n (%) | ||||
| First line | 32 (26.4) | 21 (23.9) | 11 (33.3) | 0.293 |
| Subsequent line | 89 (72.7) | 67 (76.1) | 22 (66.7) | |
| Number of treatment cycles, median [range] | 8 [3.0–17.5] | 5 [2.0–11.6] | 14 [5.5–27.5] | <0.001 |
| Number of months under IO, median [range] | 4 [1.0–10.0] | 3 [1.0–6.0] | 10 [4.0–17.0] | <0.001 |
SD, standard deviation; COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed death 1 ligand; KRAS, Kirsten rat sarcoma viral oncogene homolog; EGFR, epidermal growth factor receptor; BRAF, V-raf murine sarcoma viral oncogene homolog B1; ALK, anaplastic lymphoma kinase; NGS, next generation sequencing; IO, immunotherapy.